Harrow Health acquires US rights to four eye drops
Harrow Health acquired the United States commercialization rights to four ophthalmic drops from Novartis, according to a press release.
The acquisition includes the 1% and 0.5% formulations of Iopidine (apraclonidine hydrochloride), Maxitrol 0.1% (neomycin and polymyxin B sulfate and dexamethasone) and Moxeza 0.5% (moxifloxacin hydrochloride).
The company plans to sell, market and distribute the products through subsidiary, ImprimisRx. Novartis will retain commercial rights outside of the U.S.
“These acquisitions, along with previously announced transactions for AMP-100, MAQ-100, and the expansion of our relationship to sell and market Dexycu, are consistent with our strategic mission to leverage the ImprimisRx commercial platform by adding high-value FDAapproved products into our family of ophthalmic pharmaceutical products,” Harrow Health CEO, Mark L. Baum, said in the release. “We are excited about the benefits these newest products provide our more than 10,000 customers, and we expect ImprimisRx’s commercial and distribution platform to be a tremendous advantage in the lifecycle management of these clinically valuable medicines.”